Get started
Author

Amanda Gonzales

Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
2017 · Boris Decourt, Denise Drumm-Gurnee, et al. · Current Alzheimer Research · 57
Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study
2012 · Boris Decourt, Aaron Walker, et al. · Platelets · 20
Development of a specific ELISA to measure BACE1 levels in human tissues
2011 · Amanda Gonzales, Boris Decourt, et al. · Journal of Neuroscience Methods · 16
BACE1 Levels by APOE Genotype in Non-Demented and Alzheimer’s Post-Mortem Brains
2013 · Boris Decourt, Amanda Gonzales, et al. · Current Alzheimer Research · 11
PDF
Platelet BACE1 levels as a possible biomarker for Alzheimer’s disease
2013 · Boris Decourt, Aaron Walker, et al. · Molecular Neurodegeneration · 1
PDF
P1–031: Lenalidomide as an antineuroinflammatory and BACE1 inhibitor: Pilot study on APP23 mice
2013 · Boris Decourt, Aaron Walker, et al. · Alzheimer s & Dementia · 1
P1‐216: Preclinical testing of lenalidomide as anti‐amyloid treatment for Alzheimer's disease
2012 · Boris Decourt, Aaron Walker, et al. · Alzheimer s & Dementia · 1
P1–349: A phase II double‐blind, placebo‐controlled randomized trial of an escalating dose of thalidomide in the treatment of Alzheimer's disease: Baseline characteristics
2013 · Marwan Sabbagh, Boris Decourt, et al. · Alzheimer s & Dementia
P1‐077: Alzheimer's disease subjects carrying the APOE4 allele have lower brain BACE1 levels than APOE3 carriers
2011 · Boris Decourt, Marwan Sabbagh, et al. · Alzheimer s & Dementia
P2‐030: Are platelet BACE1 levels altered in Alzheimer's disease patients?
2011 · Boris Decourt, Amanda Gonzales, et al. · Alzheimer s & Dementia
Works count: 10
Citation count: 107
H-index: 4
I10-index: 4
Year
Topic
Type